ArticleChemistry & biodiversity2026
Targeting Staphylococcus aureus Biofilms Through Aurisin Derivatives From Neonothopanus nambi of African Origin.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Staphylococcus aureus Biofilms Through Aurisin Derivatives From Neonothopanus nambi of African Origin.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Biofilm formation is a key survival strategy among microorganisms and a major factor contributing to chronic and treatment-resistant infections. Staphylococcus aureus is a key biofilm-forming pathogen associated with persistent and life-threatening infections. As part of our ongoing search for novel anti-biofilm agents from Basidiomycota of tropical rainforests, we investigated the metabolome of the African fungus Neonothopanus nambi. This study led to the isolation of four dimeric aristolane-type sesquiterpenoids, aurisins D, B, A, and G (1-4), along with two monomeric sesquiterpenoids, nambinone C (5) and axinysone B (6), and methyl 4-butyramidobenzoate (7). All compounds were assessed for their antimicrobial and cytotoxic activities, as well as their ability to inhibit and eradicate S. aureus biofilms. The dimeric sesquiterpenoids (1-4) exhibited potent antibiofilm effects, with aurisin B (2) inhibiting biofilm formation by over 70% at a concentration of 1 µg/mL, well below its minimum inhibitory concentration. Confocal laser scanning microscopy further confirmed the pronounced anti-biofilm effects of aurisins D and B (1 and 2). Structure-activity relationship analysis suggests that both dimerization and hydroxylation contribute to enhanced activity. Despite some cytotoxic effects, these dimeric aristolane-type sesquiterpenoids from N. nambi represent promising leads for the development of novel anti-infective strategies targeting S. aureus biofilms, with potential applications beyond systemic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.